The 27th JFCR－ISCC
December 13-14, 2023
Miraikan - The National Museum of Emerging Science and Innovation 7F
2-3-6, Aomi, Koto-ku, Tokyo, Japan
December 13
12:00-12:30
Committee meeting
Opening Remark
12:50-13:00
Naoya Fujita (Cancer Chemotherapy Center, JFCR, Tokyo)
Opening remark
ITargeting RAS/RAF/MAPK Pathway
Chairpersons: Ryan Corcoran (Massachusetts General Hospital Cancer Center, Boston, MA, USA),
Masanobu Oshima (Kanazawa University, Ishikawa)
13:00-13:30
Hiromichi Ebi (Aichi Cancer Center Research Institute, Aichi)
Genetic and non-genetic mechanisms of resistance to KRAS inhibitors
13:30-14:10
Zhe Chen (Revolution Medicines, Redwood City, CA, USA)
Targeting the oncogenic state of RAS with TriComplex inhibitors
14:10-14:40
Masahiko Hayakawa (Astellas Pharma Inc., Ibaraki)
KRAS G12D degrader: ASP3082
14:40-15:20
Ryan Corcoran (Massachusetts General Hospital Cancer Center, Boston, MA, USA)
Harnessing the immune response to BRAF inhibition in BRAF V600E colorectal cancer
15:20-15:30
Discussion
Meet-the-Expert Session
Chairperson: Seiji Yano (Kanazawa University, Ishikawa)
15:30-16:10
Jaap Verweij (Erasmus University Medical Center, Rotterdam, The Netherlands)
Developing a novel TKI for a rare indication in a crowded market, DO-2 as example
16:10-16:30
Coffee Break
II Special Session: History and Future of Cancer Chemotherapy
Chairpersons: Jaap Verweij (Erasmus University Medical Center, Rotterdam, The Netherlands),
Shunji Takahashi (Cancer Institute Hospital, JFCR, Tokyo)
16:30-17:10
Yves Pommier (National Cancer Institute, NIH, Bethesda, MD, USA)
Schlafen 11 at the intersection of genomics and proteotoxic stress
17:10-17:40
Hiroyuki Seimiya (Cancer Chemotherapy Center, JFCR, Tokyo)
Targeting tankyrase-specific PARylation for cancer therapy
17:40-18:20
Bruce A. Chabner (Massachusetts General Hospital Cancer Center, Boston, MA, USA)
History and future of cancer therapy
18:20-18:30
Discussion
Poster Viewing
18:30-19:10
December 14
III Toward Development of Next-generation Cancer Immunotherapies
Chairpersons: Sacha Gnjatic (Icahn School of Medicine at Mount Sinai, New York, NY, USA),
Hiroyoshi Nishikawa (National Cancer Center Research Institute, Tokyo / Nagoya University, Aichi)
9:00-9:30
Shohei Koyama (EPOC, National Cancer Center, Chiba)
Adaptive and acquired resistance to cancer immunotherapy
9:30-10:10
Sacha Gnjatic (Icahn School of Medicine at Mount Sinai, New York, NY, USA)
Guiding new immunotherapies with purposefully designed immune monitoring
10:10-10:50
Ping-Chih Ho (University of Lausanne, Epalinges, Switzerland)
Re-directing T cell immune response by tailoring mitochondrial programming
10:50-11:00
Discussion
Poster Presentation and Discussion
Chairperson: Manabu Kawada (Institute of Microbial Chemistry, Tokyo)
11:00-12:00
2-3 min flash talks and discussion
Jin Lee (Cancer Chemotherapy Cencer, JFCR, Tokyo)
BRD4-dependent induction of ALDH1A3 determines the early-phase drug tolerance in gastric cancer
Masahito Sugino (The University of Tokyo, Tokyo)
The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets
Nobuyuki Kondo (Cancer Chemotherapy Center, JFCR, Tokyo)
Detection of low-dose ligand dependent drug-resistance through loss of tumor suppressor genes in ALK/ROS1 positive NSCLC
Yuya Murase (Kanazawa University, Ishikawa)
Elucidation of trastuzumab deruxtecan resistance mechanism of HER2-positive human gastric cancer cells.
SungGi Chi (National Cancer Center East, Chiba)
Clinical impact of clonal hematopoiesis in patients with acute myeloid leukemia
Junya Iwasaki (Taiho Pharmaceutical Co., Ltd., Ibaraki)
TAS3351 is a mutation-selective reversible EGFR inhibitor that overcomes the T790M and C797S resistance mutations
Takayuki Kamikawa (Chugai Pharmaceutical Co., Ltd., Kanagawa)
SAIL66, a next generation of T cell engager targeting CLDN6, potentiates efficacy through binding CD3/CD137
Taisuke Nakazawa (Astellas Pharma Inc., Ibaraki)
ASP2138, a bispecific antibody targeting claudin 18.2 and CD3 in a 2+1 format, exhibits selective activity against claudin 18.2-positive tumor models
Luncheon Seminar (Supported by Toppan Inc.)
Chairperson: Kensei Yamaguchi (Cancer Institute Hospital, JFCR, Tokyo)
12:10-13:00
Michiya Matsusaki (Osaka University, Osaka)
Design of cell microenvironments for construction of three-dimensional tissue models
13:00-13:10
Break
IV Cell Therapy and Multifunctional Antibodies
Chairpersons: Ping-Chih Ho (University of Lausanne, Epalinges, Switzerland ),
Yoshihiro Hayakawa (University of Toyama, Toyama)
13:10-13:40
Naoki Hosen (Osaka University, Osaka)
Identification of novel target antigens of CAR T cell therapy for hematological cancers
13:40-14:10
Hirofumi Mikami (Chugai Pharmaceutical Co., Ltd., Kanagawa)
Next generation T-cell engagers
14:10-14:20
Discussion
V New Drugs under Clinical or Preclinical Evaluations
Chairpersons: Yves Pommier(National Cancer Institute, NIH, Bethesda, MD, USA),
Shigehisa Kitano (Cancer Institute Hospital, JFCR, Tokyo)
14:20-14:50
Masanori Okaniwa (Takeda Pharmaceutical Co., Ltd., Lexington, MA, USA)
COnditional Bispecific Redirection Activation (COBRA) T cell engagers: Solid tumor pipeline strategy and ongoing clinical trials
14:50-15:20
Sosuke Nakamura (MSD K.K., Tokyo)
Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289, MK-3543) for the Treatment of Essential Thrombocythemia (ET)
15:20-16:00
Paul Workman (The Institute of Cancer Research, Surrey, UK)
NXP800: a first-in-class, orally available, clinical-stage, investigational activator of the integrated stress response for treatment of ARID1A-mutated, platinum-resistant ovarian cancer
16:00-16:10
Discussion
Closing Remark
16:10-16:20
Yves Pommier (National Cancer Institute, NIH, Bethesda, MD, USA)
Closing remark